PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28881435-0 2017 Versatile Method for the Site-Specific Modification of DNA with Boron Clusters: Anti-Epidermal Growth Factor Receptor (EGFR) Antisense Oligonucleotide Case. Oligonucleotides 135-150 epidermal growth factor receptor Homo sapiens 80-117 31925985-7 2020 An anti-sense oligonucleotide (ASO) against ARL4C (ARL4C ASO-1316) inhibited RAS-related C3 botulinum toxin substrate activity and nuclear import of Yes-associated protein and transcriptional coactivator with PDZ-binding motif, and suppressed in vitro proliferation and migration of lung cancer cells with KRAS or epidermal growth factor receptor (EGFR) mutations. Oligonucleotides 14-29 epidermal growth factor receptor Homo sapiens 314-346 31925985-7 2020 An anti-sense oligonucleotide (ASO) against ARL4C (ARL4C ASO-1316) inhibited RAS-related C3 botulinum toxin substrate activity and nuclear import of Yes-associated protein and transcriptional coactivator with PDZ-binding motif, and suppressed in vitro proliferation and migration of lung cancer cells with KRAS or epidermal growth factor receptor (EGFR) mutations. Oligonucleotides 14-29 epidermal growth factor receptor Homo sapiens 348-352 31164704-3 2019 In the current study, novel wild-type blocking (WTB) oligonucleotides modified with phosphorothioate or inverted dT at the 5"-termini were designed to precisely detect 11 common deletion mutations in exon 19 of EGFR gene (E19del) using a WTB-PCR assay. Oligonucleotides 53-69 epidermal growth factor receptor Homo sapiens 211-215 3003706-1 1985 We screened a gene library constructed with human leukocyte chromosomal DNA fragments with an oligonucleotide probe complementary to the middle part of the cDNA for the human epidermal growth factor receptor. Oligonucleotides 94-109 epidermal growth factor receptor Homo sapiens 175-207 29748615-5 2018 We used CRISPR/Cas9 system to target a commonly occurring EGFR point mutation, L858R, with an oligonucleotide guide that recognizes L858R as the suitable protospacer-adjacent motif (PAM) sequence for DNA cleavage. Oligonucleotides 94-109 epidermal growth factor receptor Homo sapiens 58-62 29514240-0 2018 Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. Oligonucleotides 139-155 epidermal growth factor receptor Homo sapiens 28-60 28881435-0 2017 Versatile Method for the Site-Specific Modification of DNA with Boron Clusters: Anti-Epidermal Growth Factor Receptor (EGFR) Antisense Oligonucleotide Case. Oligonucleotides 135-150 epidermal growth factor receptor Homo sapiens 119-123 28832537-2 2017 High metallacarborane-loaded antisense oligonucleotides (ASOs) targeting epidermal growth factor receptor (EGFR) were synthesized through post-synthetic Cu (I)-assisted "click" conjugation of alkyne-modified DNA-oligonucleotides with a boron cluster alkyl azide component. Oligonucleotides 39-55 epidermal growth factor receptor Homo sapiens 73-105 28832537-2 2017 High metallacarborane-loaded antisense oligonucleotides (ASOs) targeting epidermal growth factor receptor (EGFR) were synthesized through post-synthetic Cu (I)-assisted "click" conjugation of alkyne-modified DNA-oligonucleotides with a boron cluster alkyl azide component. Oligonucleotides 39-55 epidermal growth factor receptor Homo sapiens 107-111 23534780-0 2013 EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. Oligonucleotides 15-31 epidermal growth factor receptor Homo sapiens 0-4 28425453-9 2017 Overall, we demonstrate a novel mechanism of action for CL4 related with integrin alphavbeta3-EGFR interaction, that may help to develop new oligonucleotide-based strategy addressing unmet need for TNBCs therapy. Oligonucleotides 141-156 epidermal growth factor receptor Homo sapiens 94-98 23953842-8 2013 Recently, many other agents like peptides, nanobodies, affibodies and antisense oligonucleotide have also shown better efficacy in targeting and inhibiting EGFR. Oligonucleotides 80-95 epidermal growth factor receptor Homo sapiens 156-160 28272528-6 2017 Degradation of Poly(A), Poly(C), Poly(G), Poly(I), Poly(T), and Poly(U) oligomers in the presence of EGFR and ATP correlated with the lower ability of reaction products to pair with complementary oligonucleotides. Oligonucleotides 196-212 epidermal growth factor receptor Homo sapiens 101-105 23571736-2 2013 The Toll-like receptor 9 agonist immune modulatory oligonucleotide (IMO) exhibits direct antitumour and antiangiogenic activity and cooperates with both epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors. Oligonucleotides 51-66 epidermal growth factor receptor Homo sapiens 153-185 23571736-2 2013 The Toll-like receptor 9 agonist immune modulatory oligonucleotide (IMO) exhibits direct antitumour and antiangiogenic activity and cooperates with both epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors. Oligonucleotides 51-66 epidermal growth factor receptor Homo sapiens 187-191 23395887-0 2013 Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. Oligonucleotides 44-59 epidermal growth factor receptor Homo sapiens 106-110 23534780-0 2013 EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. Oligonucleotides 15-31 epidermal growth factor receptor Homo sapiens 73-77 23534780-4 2013 For this aim we used FITC-labeled EGFR antisense oligonucleotides encapsulated with PAMAM nanoparticles to inhibit EGFR expression. Oligonucleotides 49-65 epidermal growth factor receptor Homo sapiens 115-119 21890455-2 2011 We previously showed that the novel Toll-like receptor 9 (TLR9) agonist immunomodulatory oligonucleotide (IMO) has a strong in vivo activity in colorectal cancer models by interfering with EGFR-related signaling and synergizing with the anti-EGFR monoclonal antibody cetuximab. Oligonucleotides 89-104 epidermal growth factor receptor Homo sapiens 189-193 23103856-7 2013 Depletion of oncogenic Ras with siRNA oligonucleotides relieves this negative feedback, leading to the hyperactivation of EGFR and wild-type Ras signaling. Oligonucleotides 38-54 epidermal growth factor receptor Homo sapiens 122-126 21573974-0 2012 Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR. Oligonucleotides 105-121 epidermal growth factor receptor Homo sapiens 149-153 21890455-2 2011 We previously showed that the novel Toll-like receptor 9 (TLR9) agonist immunomodulatory oligonucleotide (IMO) has a strong in vivo activity in colorectal cancer models by interfering with EGFR-related signaling and synergizing with the anti-EGFR monoclonal antibody cetuximab. Oligonucleotides 89-104 epidermal growth factor receptor Homo sapiens 242-246 21325655-6 2011 METHODS: We enriched the target by exposing genomic DNA to an EGFR exon 20-specific biotinylated oligonucleotide, followed by binding to streptavidin beads. Oligonucleotides 97-112 epidermal growth factor receptor Homo sapiens 62-66 22321542-2 2011 METHODS: Optimized oligonucleotide probe method was applied to detect EGFR mutations involving exons 18 - 21 using formalin fixed paraffin embedded tissue specimens of 309 NSCLC patients. Oligonucleotides 19-34 epidermal growth factor receptor Homo sapiens 70-74 22321542-11 2011 Optimized oligonucleotide probe method is a sensitive and convenient method for the detection of EGFR mutations. Oligonucleotides 10-25 epidermal growth factor receptor Homo sapiens 97-101 21756831-0 2011 [Comparison of real-time quantitative PCR and allele-specific oligonucleotide PCR for detections of L858R mutation in epidermal growth factor receptor gene exon 21]. Oligonucleotides 62-77 epidermal growth factor receptor Homo sapiens 118-150 19903791-3 2009 We previously found that a novel toll-like receptor 9 agonist, referred to as immune modulatory oligonucleotide (IMO) and currently under clinical investigation, acts through epidermal growth factor receptor (EGFR) and shows direct antiangiogenic effects by cooperating with anti-EGFR or anti-VEGF drugs, thus interfering with cancer cells and microenvironment. Oligonucleotides 96-111 epidermal growth factor receptor Homo sapiens 175-207 19836242-3 2009 Because hyperphosphorylation of EGFR is involved in oncogenic pathways, we performed an unbiased screen of small interfering RNA (siRNA) oligonucleotides targeting all human tyrosine phosphatases. Oligonucleotides 137-153 epidermal growth factor receptor Homo sapiens 32-36 19937163-0 2010 Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR. Oligonucleotides 117-133 epidermal growth factor receptor Homo sapiens 161-165 19903791-3 2009 We previously found that a novel toll-like receptor 9 agonist, referred to as immune modulatory oligonucleotide (IMO) and currently under clinical investigation, acts through epidermal growth factor receptor (EGFR) and shows direct antiangiogenic effects by cooperating with anti-EGFR or anti-VEGF drugs, thus interfering with cancer cells and microenvironment. Oligonucleotides 96-111 epidermal growth factor receptor Homo sapiens 209-213 19903791-3 2009 We previously found that a novel toll-like receptor 9 agonist, referred to as immune modulatory oligonucleotide (IMO) and currently under clinical investigation, acts through epidermal growth factor receptor (EGFR) and shows direct antiangiogenic effects by cooperating with anti-EGFR or anti-VEGF drugs, thus interfering with cancer cells and microenvironment. Oligonucleotides 96-111 epidermal growth factor receptor Homo sapiens 280-284 19766894-6 2009 DNA binding activity of EGFR was analyzed by EMSA using nuclear extracts and a radiolabeled oligonucleotide probe representing the AT-rich minimal sequence (ATRS). Oligonucleotides 92-107 epidermal growth factor receptor Homo sapiens 24-28 19347870-6 2009 The transfection of specific antisense (AS) oligonucleotides strengthened our hypothesis that EGFR reduction caused changes in the proliferation/differentiation pattern comparable to those induced by ER ligands. Oligonucleotides 44-60 epidermal growth factor receptor Homo sapiens 94-98 18207161-5 2008 New binders were selected with phage display technology, using a single oligonucleotide in a single-library effort, and the best second-generation binders had an approximately 30-fold improvement in affinity (K(d)=5-10 nM) for the soluble extracellular domain of EGFR in biospecific interaction analysis using Biacore. Oligonucleotides 72-87 epidermal growth factor receptor Homo sapiens 263-267 17922545-7 2007 We demonstrate the flexibility of the oligonucleotide-based approach by preparing contrast agents conjugated to folate, EGF peptide, and anti-EGFR antibodies. Oligonucleotides 38-53 epidermal growth factor receptor Homo sapiens 142-146 18025070-0 2008 Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Oligonucleotides 93-109 epidermal growth factor receptor Homo sapiens 50-82 18025070-3 2008 Targeting EGFR via intratumoral administration of phosphorothioate-modified antisense oligonucleotides has antitumor efficacy in xenograft models of SCCHN. Oligonucleotides 86-102 epidermal growth factor receptor Homo sapiens 10-14 18025070-8 2008 Administration of EGFR antisense oligonucleotides in combination with docetaxel improved antitumor efficacy and resulted in lower expression levels of EGFR, fewer proliferating cells, and more apoptotic cells in the tumors compared with controls. Oligonucleotides 33-49 epidermal growth factor receptor Homo sapiens 18-22 18025070-8 2008 Administration of EGFR antisense oligonucleotides in combination with docetaxel improved antitumor efficacy and resulted in lower expression levels of EGFR, fewer proliferating cells, and more apoptotic cells in the tumors compared with controls. Oligonucleotides 33-49 epidermal growth factor receptor Homo sapiens 151-155 18025070-9 2008 Systemic administration of phosphorothioated EGFR antisense oligonucleotides for 30 days increased the retention of docetaxel in the tumor by approximately 4-fold compared with tumors treated with docetaxel alone or docetaxel and EGFR sense oligonucleotides (P < 0.05). Oligonucleotides 60-76 epidermal growth factor receptor Homo sapiens 45-49 18025070-9 2008 Systemic administration of phosphorothioated EGFR antisense oligonucleotides for 30 days increased the retention of docetaxel in the tumor by approximately 4-fold compared with tumors treated with docetaxel alone or docetaxel and EGFR sense oligonucleotides (P < 0.05). Oligonucleotides 60-76 epidermal growth factor receptor Homo sapiens 230-234 18025070-9 2008 Systemic administration of phosphorothioated EGFR antisense oligonucleotides for 30 days increased the retention of docetaxel in the tumor by approximately 4-fold compared with tumors treated with docetaxel alone or docetaxel and EGFR sense oligonucleotides (P < 0.05). Oligonucleotides 241-257 epidermal growth factor receptor Homo sapiens 45-49 17972023-1 2008 Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha) (MR1) and its binding site, the epidermal growth factor receptor (EGFR) (MR2), are efficacious against the UACC 897 breast, PC-3 and LNCaP prostate, and T98G glioblastoma tumor lines in both in vitro and in vivo studies. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 121-153 17972023-1 2008 Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha) (MR1) and its binding site, the epidermal growth factor receptor (EGFR) (MR2), are efficacious against the UACC 897 breast, PC-3 and LNCaP prostate, and T98G glioblastoma tumor lines in both in vitro and in vivo studies. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 155-159 17972023-1 2008 Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha) (MR1) and its binding site, the epidermal growth factor receptor (EGFR) (MR2), are efficacious against the UACC 897 breast, PC-3 and LNCaP prostate, and T98G glioblastoma tumor lines in both in vitro and in vivo studies. Oligonucleotides 28-34 epidermal growth factor receptor Homo sapiens 121-153 17636117-3 2007 We recently discovered that a synthetic agonist of TLR9, immune modulatory oligonucleotide (IMO), acts by impairing epidermal growth factor receptor (EGFR) signaling and potently synergizes with anti-EGFR antibody cetuximab in GEO human colon cancer xenografts, whereas it is ineffective in VEGF-overexpressing cetuximab-resistant GEO cetuximab-resistant (GEO-CR) tumors. Oligonucleotides 75-90 epidermal growth factor receptor Homo sapiens 116-148 17636117-3 2007 We recently discovered that a synthetic agonist of TLR9, immune modulatory oligonucleotide (IMO), acts by impairing epidermal growth factor receptor (EGFR) signaling and potently synergizes with anti-EGFR antibody cetuximab in GEO human colon cancer xenografts, whereas it is ineffective in VEGF-overexpressing cetuximab-resistant GEO cetuximab-resistant (GEO-CR) tumors. Oligonucleotides 75-90 epidermal growth factor receptor Homo sapiens 150-154 17636117-3 2007 We recently discovered that a synthetic agonist of TLR9, immune modulatory oligonucleotide (IMO), acts by impairing epidermal growth factor receptor (EGFR) signaling and potently synergizes with anti-EGFR antibody cetuximab in GEO human colon cancer xenografts, whereas it is ineffective in VEGF-overexpressing cetuximab-resistant GEO cetuximab-resistant (GEO-CR) tumors. Oligonucleotides 75-90 epidermal growth factor receptor Homo sapiens 200-204 17917084-1 2007 In previous studies we demonstrated that antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha [MR1]), its binding site the epidermal growth factor receptor (EGFR [MR2]), and the anti-apoptosis protein bcl-2 (MR4) are efficacious against prostate tumors. Oligonucleotides 51-67 epidermal growth factor receptor Homo sapiens 158-190 17917084-1 2007 In previous studies we demonstrated that antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha [MR1]), its binding site the epidermal growth factor receptor (EGFR [MR2]), and the anti-apoptosis protein bcl-2 (MR4) are efficacious against prostate tumors. Oligonucleotides 51-67 epidermal growth factor receptor Homo sapiens 192-196 17848743-1 2007 Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha) (MR1) and its binding site, the epidermal growth factor receptor (EGFR) (MR2), are efficacious against PC-3 and LNCaP prostate tumors. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 121-153 16597093-2 2006 EGFR thus provides a rational target for cancer therapies and a number of strategies influencing this receptor, and its downstream signal cascades, including monoclonal antibodies, tyrosine-kinase inhibitors, antisense oligonucleotides inhibiting EGFR synthesis and antibody-based immunoconjugates, have been evaluated. Oligonucleotides 219-235 epidermal growth factor receptor Homo sapiens 0-4 17848743-1 2007 Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha) (MR1) and its binding site, the epidermal growth factor receptor (EGFR) (MR2), are efficacious against PC-3 and LNCaP prostate tumors. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 155-159 17848743-1 2007 Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha) (MR1) and its binding site, the epidermal growth factor receptor (EGFR) (MR2), are efficacious against PC-3 and LNCaP prostate tumors. Oligonucleotides 28-34 epidermal growth factor receptor Homo sapiens 121-153 17136230-1 2006 Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the epidermal growth factor receptor (EGFR; MR(2)), have proven efficacious against PC-3 and LNCaP prostate tumors when evaluated in both in vitro and in vivo models. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 122-154 17136230-1 2006 Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the epidermal growth factor receptor (EGFR; MR(2)), have proven efficacious against PC-3 and LNCaP prostate tumors when evaluated in both in vitro and in vivo models. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 156-160 17136230-1 2006 Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the epidermal growth factor receptor (EGFR; MR(2)), have proven efficacious against PC-3 and LNCaP prostate tumors when evaluated in both in vitro and in vivo models. Oligonucleotides 28-34 epidermal growth factor receptor Homo sapiens 122-154 17136230-1 2006 Antisense oligonucleotides (oligos) against transforming growth factor-alpha (TGF-alpha; MR(1)) and its binding site, the epidermal growth factor receptor (EGFR; MR(2)), have proven efficacious against PC-3 and LNCaP prostate tumors when evaluated in both in vitro and in vivo models. Oligonucleotides 28-34 epidermal growth factor receptor Homo sapiens 156-160 12665682-1 2003 Antisense oligonucleotides (oligos) directed against mRNA-encoding transforming growth factor-alpha (TGF-alpha) and the epidermal growth factor receptor (EGFR) have demonstrated in vitro and in vivo efficacy against prostate cancer tumor models. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 120-152 16870352-2 2006 Antisense oligonucleotides (oligos) directed against transforming growth factor-alpha (TGF-alpha) and its binding site, the epidermal growth factor receptor (EGFR), have demonstrated in vitro and in vivo efficacy against both the PC-3 and LNCaP prostate tumor models. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 124-156 16870352-2 2006 Antisense oligonucleotides (oligos) directed against transforming growth factor-alpha (TGF-alpha) and its binding site, the epidermal growth factor receptor (EGFR), have demonstrated in vitro and in vivo efficacy against both the PC-3 and LNCaP prostate tumor models. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 158-162 16870352-2 2006 Antisense oligonucleotides (oligos) directed against transforming growth factor-alpha (TGF-alpha) and its binding site, the epidermal growth factor receptor (EGFR), have demonstrated in vitro and in vivo efficacy against both the PC-3 and LNCaP prostate tumor models. Oligonucleotides 28-34 epidermal growth factor receptor Homo sapiens 124-156 16870352-2 2006 Antisense oligonucleotides (oligos) directed against transforming growth factor-alpha (TGF-alpha) and its binding site, the epidermal growth factor receptor (EGFR), have demonstrated in vitro and in vivo efficacy against both the PC-3 and LNCaP prostate tumor models. Oligonucleotides 28-34 epidermal growth factor receptor Homo sapiens 158-162 15599851-7 2004 Antisense strategies use synthesized DNA or RNA oligonucleotides to block the translation of the mRNA sequences that code for the production of the EGFR or other proteins with a role in EGFR-mediated cell signaling. Oligonucleotides 48-64 epidermal growth factor receptor Homo sapiens 148-152 15599851-7 2004 Antisense strategies use synthesized DNA or RNA oligonucleotides to block the translation of the mRNA sequences that code for the production of the EGFR or other proteins with a role in EGFR-mediated cell signaling. Oligonucleotides 48-64 epidermal growth factor receptor Homo sapiens 186-190 14688027-6 2004 In contrast, down-regulation of Id-1 in androgen-independent DU145 cells by its antisense oligonucleotides resulted in suppression of EGF-R expression at both transcriptional and protein levels. Oligonucleotides 90-106 epidermal growth factor receptor Homo sapiens 134-139 12948863-0 2003 Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides. Oligonucleotides 169-185 epidermal growth factor receptor Homo sapiens 56-88 16075456-2 2005 The present study employed Affymetrix oligonucleotide arrays to profile genes induced by ligand-activated EGFR with the receptor either moderately expressed or overexpressed at an in-itself transforming level. Oligonucleotides 38-53 epidermal growth factor receptor Homo sapiens 106-110 15720189-8 2005 Moreover, MDM2 antisense oligonucleotides potentiate the effect of epidermal growth factor receptor (EGFR) inhibitors by affecting in vitro and in vivo proliferation, apoptosis and protein expression in hormone-refractory and hormone-dependent human prostate cancer cells. Oligonucleotides 25-41 epidermal growth factor receptor Homo sapiens 67-99 15720189-8 2005 Moreover, MDM2 antisense oligonucleotides potentiate the effect of epidermal growth factor receptor (EGFR) inhibitors by affecting in vitro and in vivo proliferation, apoptosis and protein expression in hormone-refractory and hormone-dependent human prostate cancer cells. Oligonucleotides 25-41 epidermal growth factor receptor Homo sapiens 101-105 14763145-8 2003 It is a matter of humanized monoclonal antibodies, such as C225 (cetuximab), targeted against EGFR, or small molecules inhibiting tyrosine kinase activity of EGFR including ZD1839 (Iressa), OS1774 (Tarceva) or CI1033, and last antisense oligonucleotides. Oligonucleotides 237-253 epidermal growth factor receptor Homo sapiens 158-162 12665682-1 2003 Antisense oligonucleotides (oligos) directed against mRNA-encoding transforming growth factor-alpha (TGF-alpha) and the epidermal growth factor receptor (EGFR) have demonstrated in vitro and in vivo efficacy against prostate cancer tumor models. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 154-158 12665682-1 2003 Antisense oligonucleotides (oligos) directed against mRNA-encoding transforming growth factor-alpha (TGF-alpha) and the epidermal growth factor receptor (EGFR) have demonstrated in vitro and in vivo efficacy against prostate cancer tumor models. Oligonucleotides 28-34 epidermal growth factor receptor Homo sapiens 120-152 12665682-1 2003 Antisense oligonucleotides (oligos) directed against mRNA-encoding transforming growth factor-alpha (TGF-alpha) and the epidermal growth factor receptor (EGFR) have demonstrated in vitro and in vivo efficacy against prostate cancer tumor models. Oligonucleotides 28-34 epidermal growth factor receptor Homo sapiens 154-158 12063543-9 2002 EGFR antisense oligonucleotide treatment resulted in a significant reduction of VEGF protein expression compared to sense oligonucleotide control. Oligonucleotides 15-30 epidermal growth factor receptor Homo sapiens 0-4 12616956-0 2002 Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines. Oligonucleotides 55-71 epidermal growth factor receptor Homo sapiens 123-127 12616956-1 2002 Antisense oligonucleotides (oligos) directed against mRNA-encoding, transforming growth factor-alpha (TGF-alpha) and the epidermal growth factor receptor (EGFR), have been shown to significantly inhibit in vitro and in vivo growth of prostate tumor models. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 121-153 12616956-1 2002 Antisense oligonucleotides (oligos) directed against mRNA-encoding, transforming growth factor-alpha (TGF-alpha) and the epidermal growth factor receptor (EGFR), have been shown to significantly inhibit in vitro and in vivo growth of prostate tumor models. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 155-159 12063543-9 2002 EGFR antisense oligonucleotide treatment resulted in a significant reduction of VEGF protein expression compared to sense oligonucleotide control. Oligonucleotides 122-137 epidermal growth factor receptor Homo sapiens 0-4 11410862-0 2001 Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 41-73 12119273-3 2002 We contributed to the identification and development of several selective inhibitors of PKA-I, such as 8-Cl-cAMP and a hybrid DNA/RNA antisense oligonucleotide of a novel class (AS-PKA-I) and of EGFR, including mAbC225 and ZD1839 (Iressa). Oligonucleotides 144-159 epidermal growth factor receptor Homo sapiens 195-199 11830539-9 2002 Also, introduction of an antisense oligonucleotide for Egr-1 diminishes EGFR expression during hypoxia, indicating that the up-regulation of EGFR by hypoxia is mediated through Egr-1. Oligonucleotides 35-50 epidermal growth factor receptor Homo sapiens 72-76 11830539-9 2002 Also, introduction of an antisense oligonucleotide for Egr-1 diminishes EGFR expression during hypoxia, indicating that the up-regulation of EGFR by hypoxia is mediated through Egr-1. Oligonucleotides 35-50 epidermal growth factor receptor Homo sapiens 141-145 11410862-2 2001 Treatment with EGFR antisense oligonucleotides showed a dose-dependent inhibition of human GEO colon cancer cell growth in soft agar. Oligonucleotides 30-46 epidermal growth factor receptor Homo sapiens 15-19 11410862-3 2001 Western blot analysis demonstrated a significant reduction in EGFR expression after treatment with each EGFR antisense oligonucleotide. Oligonucleotides 119-134 epidermal growth factor receptor Homo sapiens 62-66 11410862-3 2001 Western blot analysis demonstrated a significant reduction in EGFR expression after treatment with each EGFR antisense oligonucleotide. Oligonucleotides 119-134 epidermal growth factor receptor Homo sapiens 104-108 11410862-6 2001 The 2 EGFR antisense MBOs retained the same biological properties of the fully phosphorothioate EGFR antisense oligonucleotides targeting the same EGFR mRNA sequences, such as blocking EGFR synthesis, inhibiting cell growth and enhancing programmed cell death in human cancer cell lines that express functional EGFRs. Oligonucleotides 111-127 epidermal growth factor receptor Homo sapiens 96-100 11410862-6 2001 The 2 EGFR antisense MBOs retained the same biological properties of the fully phosphorothioate EGFR antisense oligonucleotides targeting the same EGFR mRNA sequences, such as blocking EGFR synthesis, inhibiting cell growth and enhancing programmed cell death in human cancer cell lines that express functional EGFRs. Oligonucleotides 111-127 epidermal growth factor receptor Homo sapiens 96-100 11410862-6 2001 The 2 EGFR antisense MBOs retained the same biological properties of the fully phosphorothioate EGFR antisense oligonucleotides targeting the same EGFR mRNA sequences, such as blocking EGFR synthesis, inhibiting cell growth and enhancing programmed cell death in human cancer cell lines that express functional EGFRs. Oligonucleotides 111-127 epidermal growth factor receptor Homo sapiens 96-100 11410862-8 2001 These results show the antiproliferative activity of specific EGFR antisense oligonucleotides and allow to identify novel EGFR antisense MBOs that deserve further evaluation as potential selective anticancer agents alone or in combination with cytotoxic drugs in human carcinomas that express functional EGFRs. Oligonucleotides 77-93 epidermal growth factor receptor Homo sapiens 62-66 11484948-6 2001 The design and use (preclinical and clinical) of small molecule inhibitors, antibodies, and antisense oligonucleotides against wild-type EGFR are considered in detail as these strategies can be directly adapted to target EGFRvIII. Oligonucleotides 102-118 epidermal growth factor receptor Homo sapiens 137-141 10206071-0 1999 Antisense oligonucleotides to the epidermal growth factor receptor. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 34-66 11778757-0 2001 Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor. Oligonucleotides 60-76 epidermal growth factor receptor Homo sapiens 148-180 11778757-1 2001 Antisense oligonucleotides (oligos) complementary to mRNA encoding transforming growth factor-alpha (TGF-alpha) and its target, the epidermal growth factor receptor (EGFR), are efficacious against human prostate and breast cancers carried in athymic nude mice. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 132-164 11778757-1 2001 Antisense oligonucleotides (oligos) complementary to mRNA encoding transforming growth factor-alpha (TGF-alpha) and its target, the epidermal growth factor receptor (EGFR), are efficacious against human prostate and breast cancers carried in athymic nude mice. Oligonucleotides 10-26 epidermal growth factor receptor Homo sapiens 166-170 11778757-1 2001 Antisense oligonucleotides (oligos) complementary to mRNA encoding transforming growth factor-alpha (TGF-alpha) and its target, the epidermal growth factor receptor (EGFR), are efficacious against human prostate and breast cancers carried in athymic nude mice. Oligonucleotides 28-34 epidermal growth factor receptor Homo sapiens 132-164 11778757-1 2001 Antisense oligonucleotides (oligos) complementary to mRNA encoding transforming growth factor-alpha (TGF-alpha) and its target, the epidermal growth factor receptor (EGFR), are efficacious against human prostate and breast cancers carried in athymic nude mice. Oligonucleotides 28-34 epidermal growth factor receptor Homo sapiens 166-170 11278982-5 2001 Activation of JNK by H(2)O(2) was also inhibited by AG1478 and antisense oligonucleotides directed against the epidermal growth factor receptor (EGFR), implicating the EGFR in this process. Oligonucleotides 73-89 epidermal growth factor receptor Homo sapiens 111-143 11278982-5 2001 Activation of JNK by H(2)O(2) was also inhibited by AG1478 and antisense oligonucleotides directed against the epidermal growth factor receptor (EGFR), implicating the EGFR in this process. Oligonucleotides 73-89 epidermal growth factor receptor Homo sapiens 145-149 11278982-5 2001 Activation of JNK by H(2)O(2) was also inhibited by AG1478 and antisense oligonucleotides directed against the epidermal growth factor receptor (EGFR), implicating the EGFR in this process. Oligonucleotides 73-89 epidermal growth factor receptor Homo sapiens 168-172 10445230-2 1999 Recently, T98G has been employed to develop new types of therapy directed at limiting EGFR expression such as by administration of antisense oligonucleotides directed against EGFR encoding mRNA. Oligonucleotides 141-157 epidermal growth factor receptor Homo sapiens 86-90 10445230-2 1999 Recently, T98G has been employed to develop new types of therapy directed at limiting EGFR expression such as by administration of antisense oligonucleotides directed against EGFR encoding mRNA. Oligonucleotides 141-157 epidermal growth factor receptor Homo sapiens 175-179 10206071-6 1999 All of these antisense oligonucleotides inhibited expression of the 10 kb EGFR mRNA (range: 22-97% inhibition) compared to a scrambled control oligonucleotide or an untreated control. Oligonucleotides 23-39 epidermal growth factor receptor Homo sapiens 74-78 10206071-6 1999 All of these antisense oligonucleotides inhibited expression of the 10 kb EGFR mRNA (range: 22-97% inhibition) compared to a scrambled control oligonucleotide or an untreated control. Oligonucleotides 23-38 epidermal growth factor receptor Homo sapiens 74-78 10206071-7 1999 Expression of the less prominent 5.6 kb EGFR mRNA band was also inhibited by all but two of the parent oligonucleotides. Oligonucleotides 103-119 epidermal growth factor receptor Homo sapiens 40-44 10206071-9 1999 The reduction in the expression of EGFR mRNA by the three most potent antisense compounds was accompanied by a significant reduction of EGFR protein (90-98%) and in vitro growth inhibition of SKOV3 cells as compared to the control oligonucleotide. Oligonucleotides 231-246 epidermal growth factor receptor Homo sapiens 35-39 9285564-7 1997 The -167/-105 segment of the EGF-R promotor contains one perfect and several imperfect consensus p53-binding half sites; indeed in gel shift experiments the 62 bp -167/-105 segment as well as the oligonucleotides corresponding to two p53 consensus half-sites within the 62 bp fragment, exhibited binding to p53-containing protein complexes. Oligonucleotides 196-212 epidermal growth factor receptor Homo sapiens 29-34 9175212-5 1997 A 30mer EGF-R specific oligonucleotide was end-labeled and used to probe a dot blot filter containing the RNA from the bioptic samples. Oligonucleotides 23-38 epidermal growth factor receptor Homo sapiens 8-13 9247297-0 1997 Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Oligonucleotides 23-38 epidermal growth factor receptor Homo sapiens 125-137 9216693-5 1997 We used digoxigenin (DIG)-labeled antisense oligonucleotide probes for ISH, which demonstrated aberrant EGFR mRNA in 2 of the 26 gliomas and in 3 of the 19 human glioma xenografts. Oligonucleotides 44-59 epidermal growth factor receptor Homo sapiens 104-108 9242377-5 1997 Treatment of several SCCHN cell lines with a pair of antisense oligodeoxynucleotides directed against the translation start site and first intron-exon splice junction of the human EGFR gene resulted in decreased EGFR protein production and inhibited growth by 86% compared to a 13% reduction in cells treated with sense oligonucleotides (P=0.03). Oligonucleotides 320-336 epidermal growth factor receptor Homo sapiens 180-184 7724560-7 1995 Growth inhibition of the oligonucleotide-treated cells was probably due to reduced EGFR expression because indirect immunofluorescence staining of the cells with a monoclonal antibody against the EGFR showed an almost quantitative reduction of the EGFR in cells treated with folate-PEG-liposome-entrapped AEGFR2. Oligonucleotides 25-40 epidermal growth factor receptor Homo sapiens 83-87 9232607-2 1997 For treating these recurrent androgen-independent tumors, following hormone treatment failure, a new tier of therapy based upon growth factor deprivation has been suggested, implemented by antisense oligonucleotides (oligos) directed against mRNA encoding a critical growth regulatory autocrine loop (comprised of transforming growth factor-alpha (TGF-alpha) and its binding site, the epidermal growth factor receptor (EGFR). Oligonucleotides 199-215 epidermal growth factor receptor Homo sapiens 385-417 9232607-2 1997 For treating these recurrent androgen-independent tumors, following hormone treatment failure, a new tier of therapy based upon growth factor deprivation has been suggested, implemented by antisense oligonucleotides (oligos) directed against mRNA encoding a critical growth regulatory autocrine loop (comprised of transforming growth factor-alpha (TGF-alpha) and its binding site, the epidermal growth factor receptor (EGFR). Oligonucleotides 199-215 epidermal growth factor receptor Homo sapiens 419-423 8668679-1 1996 PURPOSE: The goal of this study was to investigate the feasibility of utilizing epidermal growth factor (EGF) receptor-mediated endocytosis to enhance cellular uptake and targeting of oligonucleotides in epithelial cancer cells. Oligonucleotides 184-200 epidermal growth factor receptor Homo sapiens 80-118 8621697-8 1996 Oligonucleotides corresponding to the AP2 binding sites found in the EGF receptor promoter showed the ability to bind AP2 and compete for the binding of a factor induced by PMA treatment. Oligonucleotides 0-16 epidermal growth factor receptor Homo sapiens 69-81 7724560-7 1995 Growth inhibition of the oligonucleotide-treated cells was probably due to reduced EGFR expression because indirect immunofluorescence staining of the cells with a monoclonal antibody against the EGFR showed an almost quantitative reduction of the EGFR in cells treated with folate-PEG-liposome-entrapped AEGFR2. Oligonucleotides 25-40 epidermal growth factor receptor Homo sapiens 196-200 7724560-7 1995 Growth inhibition of the oligonucleotide-treated cells was probably due to reduced EGFR expression because indirect immunofluorescence staining of the cells with a monoclonal antibody against the EGFR showed an almost quantitative reduction of the EGFR in cells treated with folate-PEG-liposome-entrapped AEGFR2. Oligonucleotides 25-40 epidermal growth factor receptor Homo sapiens 196-200 34064412-4 2021 These B-ASOs, built from 1,2-dicarba-closo-dodecaborane linked with two anti-EGFR antisense oligonucleotides (ASOs), form with their complementary congeners torus-like nanostructures, as previously shown by atomic force microscope (AFM) and transmission electron cryo-microscopy (cryo-TEM) imaging. Oligonucleotides 92-108 epidermal growth factor receptor Homo sapiens 77-81 7962064-15 1994 Lastly, anti-sense oligonucleotides (20 microM) to PLC gamma-1 reduced both responses in NR6 cells expressing wild-type EGFR. Oligonucleotides 19-35 epidermal growth factor receptor Homo sapiens 120-124 8439966-5 1993 In situ hybridization with antisense EGF-R oligonucleotide probes directly correlated with EGF-R mRNA and protein levels observed by Northern blot and immunohistochemistry, respectively. Oligonucleotides 43-58 epidermal growth factor receptor Homo sapiens 37-42 8439966-5 1993 In situ hybridization with antisense EGF-R oligonucleotide probes directly correlated with EGF-R mRNA and protein levels observed by Northern blot and immunohistochemistry, respectively. Oligonucleotides 43-58 epidermal growth factor receptor Homo sapiens 91-96 8439966-6 1993 In situ hybridization of paraffin-embedded sections of primary human colon carcinoma and metastases from liver and lymph node revealed cell-specific staining with EGF-R antisense oligonucleotide probes that correlated directly with Northern blot and immunohistochemistry analyses. Oligonucleotides 179-194 epidermal growth factor receptor Homo sapiens 163-168 8410483-1 1993 We describe a rapid, formamide-free, random oligomer-enhanced in situ hybridization method in formalin-fixed, paraffin-embedded tissue sections using a biotinylated oligonucleotide probe for colorimetric detection of the mRNA transcript of the epidermal growth factor receptor (EGFR) gene, a putative protooncogene. Oligonucleotides 165-180 epidermal growth factor receptor Homo sapiens 244-276 8410483-1 1993 We describe a rapid, formamide-free, random oligomer-enhanced in situ hybridization method in formalin-fixed, paraffin-embedded tissue sections using a biotinylated oligonucleotide probe for colorimetric detection of the mRNA transcript of the epidermal growth factor receptor (EGFR) gene, a putative protooncogene. Oligonucleotides 165-180 epidermal growth factor receptor Homo sapiens 278-282